[DOC] mmc2.docx - The Lancet,https://www.thelancet.com/cms/10.1016/j.eclinm.2022.101463/attachment/319ec7c5-9d00-45a7-8564-247f60ceeab1/mmc2.docx
[DOC] links.lww.com/IAE/A922,http://links.lww.com/IAE/A922
[DOC] Bevacizumab (Avastin®) – Medicare Part B Coding for Off-Label ...,https://www.aao.org/assets/2c61747f-ccc2-4bb2-aa8d-819c674e89bf/635721288768030000/avastin-coding-for-medicare-part-b-carriers-july-2015-pdf
[DOC] Petrushkin The Use of Topical Letter 2017 Accepted.docx,https://qmro.qmul.ac.uk/xmlui/bitstream/handle/123456789/19440/Petrushkin%2520The%2520Use%2520of%2520Topical%2520Letter%25202017%2520Accepted.docx%3Fsequence%3D1
[DOC] 20/2018 - Repatriation Medical Authority,http://www.rma.gov.au/assets/SOP/2018/cf9edc20bb/020.docx
[DOC] Supplemental Table 1 - Dove Medical Press,https://www.dovepress.com/get_supplementary_file.php%3Ff%3D296345.docx
[DOC] Attachment - PLOS,https://journals.plos.org/plosone/article/file%3Fid%3D10.1371/journal.pone.0263352.s003%26type%3Dsupplementary
[DOC] https://www.mass.gov/doc/recommended-decision-for-...,https://www.mass.gov/doc/recommended-decision-for-dr-hughes-0/download
[DOC] mmc1.docx,https://www.ajo.com/cms/10.1016/j.ajo.2019.02.034/attachment/72af8739-13d9-450d-bcb3-8fb96e65cb82/mmc1.docx
[DOC] GL-173-68841-Insertion-drug-eluting implant-lacrimal-canaliculus ...,https://www.oregon.gov/oha/HPA/DSI-HERC/SearchablePLdocuments/GL-173-68841-Insertion-drug-eluting%2520implant-lacrimal-canaliculus.docx
